You don't need to be concerned with company failure. If that were the case, Pure would not exercise $500k worth of oppies and put a commercial loan facility on the table. They're prudent operators and consistently deliver high percentage returns for their clients. They'd look like complete idiots if Sensera were on the verge of failure.
NanoDX is taking considerable time because of their insistence in applying for several modalities. In hindsight Biodirection probably realise this insistence was in error - yes, it would create a stir and media interest while also increasing uptake but it has taken valuable time. They need to generate ample supporting data for each modality to be evaluated by the FDA for the EUA.
Either way, the NanoDX application is not only Covid-19 but also traumatic brain injury, stroke, sepsis, etc.
SE1 Price at posting:
5.8¢ Sentiment: Buy Disclosure: Held
